Impact of the renin-angiotensin-aldosterone system on blood pressure response to intravenous enalaprilat in patients with hypertensive crises

Journal of Human Hypertension

Volumn 11, Issue 3, 1997, Pages 177-183

  Hirschl, M M ^a,b   Binder, M ^a   Bur, A ^a   Herkner, H ^a   Woisetschlager C ^a   Bieglmayer, C ^a   Laggner, A N ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiotensin II; Enalaprilat; Plasma renin activity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; RENIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 0031007665     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000404     Document Type: Article

References (37)

1. Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive heart failure. Am J Cardiol 1996; 77: 1191-1196.
2. Lawson DH et al. European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. Eur J Clin Pharmacol 1995; 49: 73-79.
3. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156; 239-240.
4. Inserra F et al. Decrease of exercise-induced microalbuminuria in patients with type 1 diabetes by means of an angiotensin-converting enzyme inhibitor. Am J Kidney Dis 1996; 27: 26-33.
5. Joint National Committee: The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1993; 153: 154-183.
6. Cleland JG et al. Severe hypertension after first dose of enalapril in heart failure. Br Med J 1985; 291: 1309-1312.
7. Reid JL. Angiotensin converting enzyme inhibitors in the elderly. Br Med J 1987; 295: 943-944.
8. Hodsman GP et al. Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J 1983; 286: 832-834.
9. Mavis GJ et al. Blood pressure response to enalaprilic acid in essential hypertension: dose-response and effect of pretreatment with furosemide. Eur J Clin Pharmacol 1985; 29: 9-15.
10. Reid JL, MacFayden J, Squire IB. Lees KR. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am Heart J 1993; 126: 794-797.
11. Hodsman GP et al. Enalapril in treatment of hypertension with renal artery stenosis. Changes in blood pressure, renin, angiotensin I and II. renal function, and body composition. Am J Med 1984; 77: 52-60.
12. Hodsman et al. Enalapril in the treatment of hypertension with renal artery stenosis. Br Med J 1983; 287: 1413-1417.
13. DiPette Dj, Ferraro JC, Evans RR, Martin M. Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor in hypertensive crises. Clin Pharmacol Ther 1985; 38: 199-204.
14. Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. J Clin Pharmacol 1986; 26: 39-43.
15. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7 (Suppl 1): 1-7.
16. Adlassnig KP, Scheithauer W. Performance evaluation of medical systems using ROC curves. Comput Biomed Res 1989; 22: 297-313.
17. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
18. Brown et al. The effectsof the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration. In: Stokes GS, Edwards KDG (eds). Drugs affecting the renin-angiotensin-aldosterone-system. S Karger: Basel, 1976, pp 230-241.
19. Robertson JIS. Angiotensin-converting enzyme inhibitors in clinical renovascular hypertension. In: Robertson JIS, Nichols G (eds). Renin-Angiotensin System Textbook. Gower Medical: London, 1993, pp 88.1-88.13.
20. Von Luterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-470.
21. Case DB, Atlas SA, Sullivan PA, Laragh JH. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril. Circulation 1981; 64: 765-771.
22. Wood JM et al. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 1985; 7: 793-803.
23. Bunkenburg B et al. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hypertension 1991; 18: 278-288.
24. Hirschl MM et al. Clinical evaluation of different dosages of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995; 155: 2217-2223.
25. Prisant LM, Carr AA, Hawkins DW. Treating hypertensive emergencies. Controlled reduction of blood pressure and protection of target organs. Postgrad Med 1993; 93: 92-96.
26. Graham DI, Jones JV. Hypertension and the cerebral circulation with special reference to the pathophysiology of central nervous system complications of treatment. In: Robertson JIS, Pickering GW (eds). The therapeutics of hypertension. Royal Society of Medicine: London, 1980, pp 105-113.
27. Reid JL, MacFayden RJ, Squire IB, Lees KR. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am Heart J 1993; 126: 794-797.
28. Hornung RS, Hillis WS. The acute hemodynamic effects of intravenous enalaprilic acid (MK422) in patients with left ventricular dysfunction. Br J Clin Pharmacol 1987; 23: 29-33.
29. Dzau VJ. Re R. Tissue angiotensinsystem in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493-498.
30. Bank AJ et al. Local forearm vasodilation with intraarterial administration of enalaprilat in humans. Clin Pharmacol Ther 1991, 50, 314-312.
31. Pontieri V, Lopes OU, Ferreira SH. Hypotensive effect of captopril: role of bradykinin and prostaglandin-like substances. Hypertension 1990;15 (Suppl): 155-158.
32. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988; 11: 239-243.
33. Anonymous: Dangerous antihypertensive treatment.Br Med J 1979;2: 228-229.
34. Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertensive emergencies. Lancet 1991; 338: 881.
35. Littenberg B, Wolfberg C. Pseudohypertension masquerading as malignant hypertension: Case report and review of the literature. Am J Med 1988; 84: 539-542.
36. Hirschl MM et al. Intravenous urapidil versus sublingual nifedipine in the treatment of hypertensive urgencies. Am J Emerg Med 1993; 11: 653-656.
37. Cressman et al. Intravenous labetalol in the management of severe hypertension and hypertensive emergencies. Am Heart J 1984; 107: 980-985.